Id |
Subject |
Object |
Predicate |
Lexical cue |
T5 |
0-35 |
Sentence |
denotes |
Watch the interview with the author |
T6 |
36-49 |
Sentence |
denotes |
Abbreviations |
T7 |
50-86 |
Sentence |
denotes |
ACE2 angiotensin‐converting enzyme 2 |
T8 |
87-133 |
Sentence |
denotes |
CDC Centers for Disease Control and Prevention |
T9 |
134-167 |
Sentence |
denotes |
COVID‐19 coronavirus disease 2019 |
T10 |
168-190 |
Sentence |
denotes |
CT computed tomography |
T11 |
191-226 |
Sentence |
denotes |
FDA US Food and Drug Administration |
T12 |
227-245 |
Sentence |
denotes |
IL‐6 interleukin‐6 |
T13 |
246-300 |
Sentence |
denotes |
RT‐PCR reverse transcription polymerase chain reaction |
T14 |
301-339 |
Sentence |
denotes |
SARS severe acute respiratory syndrome |
T15 |
340-369 |
Sentence |
denotes |
WHO World Health Organization |
T16 |
370-548 |
Sentence |
denotes |
On December 29, 2019, health authorities in China reported 27 cases of an unusual pneumonia, respiratory failure, and death linked to attendance at a live animal market in Wuhan. |
T17 |
549-661 |
Sentence |
denotes |
1 , 2 On January 7, 2020, Chinese scientists confirmed a novel coronavirus, 2019‐nCoV, as the causative agent. |
T18 |
662-948 |
Sentence |
denotes |
3 Studies revealed >80% genetic homology of 2019‐nCoV with coronaviruses of bats, presumably the original host; pangolins, suggesting this animal sold at the market as an intermediate host; and another human coronavirus, SARS‐CoV, the cause of severe acute respiratory syndrome (SARS). |
T19 |
949-1035 |
Sentence |
denotes |
3 , 4 All evidence indicates that SARS‐CoV‐2 is of animal and not laboratory origin. |
T20 |
1036-1174 |
Sentence |
denotes |
5 The World Health Organization (WHO) later named the novel virus SARS‐CoV‐2 and the related disease coronavirus disease 2019 (COVID‐19). |
T21 |
1175-1267 |
Sentence |
denotes |
2 , 3 SARS‐CoV‐2 spread quickly through communities in China and other countries (Fig. 1). |
T22 |
1268-1422 |
Sentence |
denotes |
On January 20, 2020, the first case was recognized in the United State when a 35‐year‐old man presented to an urgent care clinic in Snohomish, Washington. |
T23 |
1423-1529 |
Sentence |
denotes |
6 , 7 On January 30, 2020, WHO declared the outbreak a Public Health Emergency of International Concern. |
T24 |
1530-1584 |
Sentence |
denotes |
On March 11, 2020, WHO designated COVID‐19 a pandemic. |
T25 |
1585-1741 |
Sentence |
denotes |
Almost all countries are implementing public health measures to prevent SARS‐CoV‐2 transmission and are marshaling clinical care for patients with COVID‐19. |
T26 |
1742-1909 |
Sentence |
denotes |
This review highlights key features of SARS‐CoV‐2 infection, the epidemiology and clinical course of COVID‐19, and interventions to stop the growing COVID‐19 pandemic. |
T27 |
1910-1953 |
Sentence |
denotes |
Fig 1 Chronology of the COVID‐19 pandemic. |
T28 |
1955-1967 |
Sentence |
denotes |
Epidemiology |
T29 |
1968-2063 |
Sentence |
denotes |
By March 11, 2020, 105 countries had reported 118,319 confirmed COVID‐19 cases and 4292 deaths. |
T30 |
2064-2138 |
Sentence |
denotes |
2 Outside China, large epidemics emerged in South Korea, Iran, and Italy. |
T31 |
2139-2225 |
Sentence |
denotes |
By March 14, 2020, approximately one in four COVID‐19 cases and deaths were in Europe. |
T32 |
2226-2293 |
Sentence |
denotes |
The US epidemic accelerated, with cases doubling every 6 to 7 days. |
T33 |
2294-2417 |
Sentence |
denotes |
7 By March 29, 2020, more than 100,000 persons had COVID‐19 in the United States, the largest burden of COVID‐19 globally. |
T34 |
2418-2565 |
Sentence |
denotes |
2 , 7 As of April 29, 2020, the COVID‐19 pandemic has grown to more than 3 million confirmed cases and more than 206,000 deaths in 179 countries. |
T35 |
2566-2658 |
Sentence |
denotes |
The United States now has more than 1 million cases (33%) and more than 50,000 deaths (25%). |
T36 |
2659-2771 |
Sentence |
denotes |
2 , 7 The potential is high for large COVID‐19 epidemics in Brazil, Russia, India, and many African countries. |
T37 |
2772-2976 |
Sentence |
denotes |
SARS‐CoV‐2 is transmitted directly through inhalation or mucosal surface exposure to an infected person’s respiratory droplets or indirectly when touching the face after contact with contaminated objects. |
T38 |
2977-3064 |
Sentence |
denotes |
2 , 4 , 7 SARS‐CoV‐2 can remain viable on environmental surfaces for up to 72 hours. |
T39 |
3065-3214 |
Sentence |
denotes |
8 SARS‐CoV‐2 is highly infectious with an R0 of approximately 2.2 to 3.0, meaning each infected person will infect about two to three other persons. |
T40 |
3215-3469 |
Sentence |
denotes |
7 Large COVID‐19 outbreaks have occurred in health care facilities, households, cruise ships, religious services (e.g., funerals), and other large gatherings 1 , 2 , 7 Individuals can transmit SARS‐CoV‐2 before, during, and after symptomatic disease. |
T41 |
3470-3544 |
Sentence |
denotes |
As many as half of individuals with SARS‐CoV‐2 infection have no symptoms. |
T42 |
3545-3546 |
Sentence |
denotes |
7 |
T43 |
3548-3569 |
Sentence |
denotes |
Clinical Presentation |
T44 |
3570-3811 |
Sentence |
denotes |
Similar to SARS‐CoV, SARS‐CoV‐2 binds to angiotensin‐converting enzyme 2 (ACE2) receptors for entry via endocytosis into alveolar epithelial cells, as well as other cells with ACE2 receptors in the heart, gastrointestinal tract, and kidneys. |
T45 |
3812-4060 |
Sentence |
denotes |
2 , 4 COVID‐19 results from SARS‐CoV‐2 replication, causing early cell death (i.e., apoptosis) and provoking a storm of proinflammatory cytokines (e.g., interleukin‐6 [IL‐6]) disrupting alveolar walls with resulting fluid accumulation in alveoli. |
T46 |
4061-4062 |
Sentence |
denotes |
4 |
T47 |
4063-4172 |
Sentence |
denotes |
The incubation period from infection to onset of COVID‐19 disease is typically 5 to 7 days (range 1‐14 days). |
T48 |
4173-4267 |
Sentence |
denotes |
1 , 2 , 7 The most common symptoms of COVID‐19 are fever and nonproductive cough (Table 1). |
T49 |
4268-4425 |
Sentence |
denotes |
1 , 4 , 7 , 9 The Centers for Disease Control and Prevention (CDC) recently added anosmia and ageusia, the loss of smell and taste, as COVID‐19 symptoms. |
T50 |
4426-4539 |
Sentence |
denotes |
7 Laboratory findings are remarkable for a normal leukocyte count, lymphopenia, and elevated C‐reactive protein. |
T51 |
4540-4706 |
Sentence |
denotes |
1 , 6 , 8 Most hospitalized patients with COVID‐19 have a bilateral ground‐glass appearance on chest computed tomography (CT) scan consistent with viral pneumonia. |
T52 |
4707-4792 |
Sentence |
denotes |
Table 1 Clinical Features of COVID‐19 in Wuhan and Multiple Other Locations in China |
T53 |
4793-4851 |
Sentence |
denotes |
Clinical Features Wuhan, China Multiple Locations, China |
T54 |
4852-4885 |
Sentence |
denotes |
Number of patients 10,999 3,062 |
T55 |
4886-4894 |
Sentence |
denotes |
Symptoms |
T56 |
4895-4910 |
Sentence |
denotes |
Fever 89% 80% |
T57 |
4911-4926 |
Sentence |
denotes |
Cough 68% 63% |
T58 |
4927-4950 |
Sentence |
denotes |
Expectoration 34% 42% |
T59 |
4951-4968 |
Sentence |
denotes |
Dyspnea 19% 34% |
T60 |
4969-4994 |
Sentence |
denotes |
Fatigue/Myalgia 38% 46% |
T61 |
4995-5013 |
Sentence |
denotes |
Headache 14% 15% |
T62 |
5014-5038 |
Sentence |
denotes |
Nausea/Vomiting 5% 10% |
T63 |
5039-5056 |
Sentence |
denotes |
Diarrhea 4% 13% |
T64 |
5057-5075 |
Sentence |
denotes |
Laboratory results |
T65 |
5076-5112 |
Sentence |
denotes |
Leukocytes in normal range 94% 70% |
T66 |
5113-5134 |
Sentence |
denotes |
Lymphopenia 83% 57% |
T67 |
5135-5173 |
Sentence |
denotes |
Increased C‐reactive protein 61% 74% |
T68 |
5174-5236 |
Sentence |
denotes |
Alanine aminotransferase above upper limit of normal 21% 29% |
T69 |
5237-5244 |
Sentence |
denotes |
Imaging |
T70 |
5245-5272 |
Sentence |
denotes |
Abnormal chest CT 86% 89% |
T71 |
5273-5319 |
Sentence |
denotes |
Bilateral infiltrates (ground glass) 56% 76% |
T72 |
5320-5364 |
Sentence |
denotes |
Acute respiratory distress syndrome 6% 20% |
T73 |
5365-5384 |
Sentence |
denotes |
Mortality 1.4% 6% |
T74 |
5385-5410 |
Sentence |
denotes |
Data are from Guna et al. |
T75 |
5411-5461 |
Sentence |
denotes |
1 and Centers for Disease Control and Prevention. |
T76 |
5462-5463 |
Sentence |
denotes |
7 |
T77 |
5464-5611 |
Sentence |
denotes |
John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. |
T78 |
5612-5794 |
Sentence |
denotes |
It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
T79 |
5795-5891 |
Sentence |
denotes |
Today, reverse transcription polymerase chain reaction (RT‐PCR) is the COVID‐19 diagnostic test. |
T80 |
5892-6041 |
Sentence |
denotes |
2 , 7 RT‐PCR sensitivity is highest for testing bronchial alveolar lavage fluid (93%) and declines for sputum (72%) and nasal swab (63%) specimens. |
T81 |
6042-6094 |
Sentence |
denotes |
10 COVID‐19 diagnosis might require repeat testing. |
T82 |
6095-6179 |
Sentence |
denotes |
2 , 7 Serological tests to detect SARS‐CoV‐2 IgM and IgG antibodies are available. |
T83 |
6180-6436 |
Sentence |
denotes |
However, because of test sensitivity and other quality concerns, the US Food and Drug Administration (FDA; https://www.fda.gov) advises current serological tests are best used for surveillance and research, and not as the sole basis for COVID‐19 diagnosis. |
T84 |
6437-6473 |
Sentence |
denotes |
COVID‐19 is commonly a mild disease. |
T85 |
6474-6657 |
Sentence |
denotes |
Of the first 72,314 COVID‐19 disease reported in China, 81% had no or mild pneumonia, 21% had severe dyspnea and radiological evidence of pulmonary disease, and 5% progressed to SARS. |
T86 |
6658-6741 |
Sentence |
denotes |
1 Individuals can be ill for a week or longer before experiencing severe symptoms. |
T87 |
6742-6853 |
Sentence |
denotes |
The risk for severe COVID‐19 disease is highest for men, older adults, and patients with certain comorbidities. |
T88 |
6854-6948 |
Sentence |
denotes |
In the United States, 80% of reported COVID‐19–related deaths are among people aged ≥65 years. |
T89 |
6949-7010 |
Sentence |
denotes |
7 , 9 , 11 Deaths are rare among persons <24 years of age. |
T90 |
7011-7203 |
Sentence |
denotes |
1 , 7 , 11 In the United States, most hospitalized patients with COVID‐19 have comorbid conditions, including obesity, hypertension, diabetes, and cardiovascular disease 7 , 11 (Table 2). |
T91 |
7204-7429 |
Sentence |
denotes |
Although listed by the CDC as a comorbid condition associated with severe COVID‐19, chronic liver disease, including cirrhosis, has not been a common comorbidity associated with hospitalization in the United States (Table 2). |
T92 |
7430-7571 |
Sentence |
denotes |
The high prevalence of comorbid conditions can explain, in part, African Americans’ increased risk for hospitalization with COVID‐19 disease. |
T93 |
7572-7662 |
Sentence |
denotes |
5 Variable comorbidity prevalence contributes to differences in national COVID mortality. |
T94 |
7663-7870 |
Sentence |
denotes |
Globally, crude fatality rates for COVID‐19 range from 0.2% in Singapore, to 2.0% to 3.0% in South Korea and Germany, to 4.3% for the United States, and to 10% to 13% in Spain, Italy, and the United Kingdom. |
T95 |
7871-7877 |
Sentence |
denotes |
2 , 5 |
T96 |
7878-7951 |
Sentence |
denotes |
Table 2 Comorbidities Among Persons With COVID‐19 Disease, United States |
T97 |
7952-7992 |
Sentence |
denotes |
Condition United States* New York City |
T98 |
7993-8053 |
Sentence |
denotes |
Not Hospitalized Hospitalized Intensive Care Hospitalized |
T99 |
8054-8085 |
Sentence |
denotes |
Patients 5143 1037 457 5700 |
T100 |
8086-8127 |
Sentence |
denotes |
One or more condition 27% 71% 78% 88% |
T101 |
8128-8143 |
Sentence |
denotes |
Obesity 42% |
T102 |
8144-8164 |
Sentence |
denotes |
Hypertension 57% |
T103 |
8165-8201 |
Sentence |
denotes |
Diabetes mellitus 6% 24% 32% 34% |
T104 |
8202-8243 |
Sentence |
denotes |
Cardiovascular disease 5% 23% 29% 18% |
T105 |
8244-8284 |
Sentence |
denotes |
Chronic renal disease 1% 9% 12% 0.6% |
T106 |
8285-8322 |
Sentence |
denotes |
Chronic liver disease 1% 1% 2% 9% |
T107 |
8323-8356 |
Sentence |
denotes |
Immunocompromised 3% 6% 9% 2% |
T108 |
8357-8374 |
Sentence |
denotes |
Mortality 21% |
T109 |
8375-8388 |
Sentence |
denotes |
Total 21% |
T110 |
8389-8410 |
Sentence |
denotes |
1 Comorbidity 88% |
T111 |
8411-8475 |
Sentence |
denotes |
* Based on data from the CDC for all 50 states and territories. |
T112 |
8476-8513 |
Sentence |
denotes |
Otherwise, data are Richardson et al. |
T113 |
8514-8516 |
Sentence |
denotes |
11 |
T114 |
8517-8664 |
Sentence |
denotes |
John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. |
T115 |
8665-8847 |
Sentence |
denotes |
It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
T116 |
8848-9081 |
Sentence |
denotes |
The search for effective therapies and a vaccine is occurring at a remarkable pace, with at least 29 studies of therapeutic agents and 5 studies of candidate vaccines registered on ClinicalTrials.org (https://www.clinicaltrials.gov). |
T117 |
9082-9236 |
Sentence |
denotes |
On May 1, 2020, the FDA granted Emergency Use Authorization of remdesivir, a broad‐spectrum antiviral nucleotide prodrug for treatment of severe COVID‐19. |
T118 |
9237-9330 |
Sentence |
denotes |
Studies of monoclonal antibodies against IL‐6 and hyperimmune immunoglobulin are in progress. |
T119 |
9331-9484 |
Sentence |
denotes |
Following reports of serious cardiac arrythmias, the FDA cautioned clinicians of prescribing hydroxychloroquine or chloroquine for treatment of COVID‐19. |
T120 |
9485-9593 |
Sentence |
denotes |
A safe and effective vaccine, if successfully developed, probably will not be available for 12 to 18 months. |
T121 |
9595-9605 |
Sentence |
denotes |
Prevention |
T122 |
9606-9869 |
Sentence |
denotes |
In the absence of a vaccine, prevention is composed of a combination of nonpharmacological interventions for suppression of transmission to R0 <1 and mitigation of the number of patients with COVID‐19 who require intensive care and mechanical respiratory support. |
T123 |
9870-10103 |
Sentence |
denotes |
12 Interventions include improved personal hygiene promotions, symptomatic screening and laboratory testing for case detection, contact tracing, household quarantine of those with transmission risks, and social distancing (Table 3). |
T124 |
10104-10285 |
Sentence |
denotes |
The United States and most other countries have implemented extensive travel restrictions, workplace and school closures, and cancellation of sporting and other large public events. |
T125 |
10286-10427 |
Sentence |
denotes |
China, South Korea, and Taiwan successfully curbed large COVID‐19 epidemics with prompt scale‐up of testing, contact tracing, and quarantine. |
T126 |
10428-10574 |
Sentence |
denotes |
2 , 4 , 7 In the United States, although testing rates are low, models suggest prevention measures are reducing transmission and future deaths. |
T127 |
10575-10794 |
Sentence |
denotes |
13 The US government recently recommended increased COVID‐19 surveillance, testing, and contact tracing with modified social distancing measures to sustain SARS‐CoV‐2 prevention while opening up education and commerce. |
T128 |
10795-10797 |
Sentence |
denotes |
14 |
T129 |
10798-10916 |
Sentence |
denotes |
Table 3 Prevention Measures to Reduce Risks for COVID‐19, Priority Populations for Testing, and Information Resources |
T130 |
10917-10988 |
Sentence |
denotes |
Prevention measures to reduce risks for COVID‐19 Practice good hygiene |
T131 |
10989-11068 |
Sentence |
denotes |
○ Wash hands often for >20 seconds with soap and water or 60% alcohol sanitizer |
T132 |
11069-11127 |
Sentence |
denotes |
○ Avoid touching eyes, nose, and mouth with unwashed hands |
T133 |
11128-11182 |
Sentence |
denotes |
○ Sneeze or cough into a tissue or inside of the elbow |
T134 |
11183-11393 |
Sentence |
denotes |
○ Disinfect surfaces and used items frequently with soap and water and Environmental Protection Agency–registered household disinfectants or bleach solution (4 teaspoons [20 mL] bleach per quart [or 1 L] water) |
T135 |
11394-11420 |
Sentence |
denotes |
Limit close social contact |
T136 |
11421-11492 |
Sentence |
denotes |
○ Learn signs and symptoms of COVID‐19, and follow local disease trends |
T137 |
11493-11623 |
Sentence |
denotes |
○ Stay home as much as possible, particularly persons who are ill, older (>65 years) adults, and those at risk for severe COVID‐19 |
T138 |
11624-11674 |
Sentence |
denotes |
○ Persons who are ill, call a health care provider |
T139 |
11675-11742 |
Sentence |
denotes |
○ Consider 2‐week supply of medications, food, and other essentials |
T140 |
11743-11832 |
Sentence |
denotes |
○ When out in public, keep social distance of at least 6 feet and wear a cloth face cover |
T141 |
11833-11866 |
Sentence |
denotes |
○ Avoid gatherings of >10 persons |
T142 |
11867-11900 |
Sentence |
denotes |
○ Work or attend school from home |
T143 |
11901-11927 |
Sentence |
denotes |
○ Avoid unnecessary travel |
T144 |
11928-11994 |
Sentence |
denotes |
○ Avoid visits to nursing homes or long‐term retirement facilities |
T145 |
11995-12035 |
Sentence |
denotes |
Protect patients and health care workers |
T146 |
12036-12136 |
Sentence |
denotes |
○ Reduce facility risks: screen for COVID‐19 symptoms on entry; reduce visits; practice telemedicine |
T147 |
12137-12187 |
Sentence |
denotes |
○ Isolate symptomatic patients as soon as possible |
T148 |
12188-12265 |
Sentence |
denotes |
○ Protect health care personnel with recommended infection‐control procedures |
T149 |
12266-12350 |
Sentence |
denotes |
Recommended testing in consultation with health care provider Hospitalized patients |
T150 |
12351-12384 |
Sentence |
denotes |
Persons with symptoms of COVID‐19 |
T151 |
12385-12415 |
Sentence |
denotes |
○ Health care facility workers |
T152 |
12416-12455 |
Sentence |
denotes |
○ Patients in long‐term care facilities |
T153 |
12456-12483 |
Sentence |
denotes |
○ Patients >65 years of age |
T154 |
12484-12535 |
Sentence |
denotes |
○ Patients with underlying conditions with symptoms |
T155 |
12536-12554 |
Sentence |
denotes |
○ First responders |
T156 |
12555-12611 |
Sentence |
denotes |
Critical infrastructure workers and others with symptoms |
T157 |
12612-12661 |
Sentence |
denotes |
Health care facility workers and first responders |
T158 |
12662-12742 |
Sentence |
denotes |
Persons mildly ill in communities with high numbers of COVID‐19 hospitalizations |
T159 |
12743-12867 |
Sentence |
denotes |
Good information resources Centers for Disease Control and Prevention: https://www.cdc.gov/coronavirus/2019-ncov/index.html |
T160 |
12868-12958 |
Sentence |
denotes |
World Health Organization: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 |
T161 |
12959-13063 |
Sentence |
denotes |
Infectious Disease Society of America: https://www.idsociety.org/public-health/COVID-19-Resource-Center/ |
T162 |
13064-13170 |
Sentence |
denotes |
American Association for the Study of Liver Diseases: https://www.aasld.org/about-aasld/covid-19-resources |
T163 |
13171-13259 |
Sentence |
denotes |
European Association for the Study of the Liver: https://easl.eu/covid-19-and-the-liver/ |
T164 |
13260-13359 |
Sentence |
denotes |
European Centre for Disease Control and Prevention: https://www.ecdc.europa.eu/en/covid-19-pandemic |
T165 |
13360-13440 |
Sentence |
denotes |
The Society for Healthcare Epidemiology of America: https://www.shea-online.org/ |
T166 |
13441-13588 |
Sentence |
denotes |
John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. |
T167 |
13589-13771 |
Sentence |
denotes |
It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |
T168 |
13773-13780 |
Sentence |
denotes |
Summary |
T169 |
13781-13904 |
Sentence |
denotes |
SARS‐CoV‐2 is a new human pathogen, readily spread via respiratory droplets and the cause of the growing COVID‐19 pandemic. |
T170 |
13905-14013 |
Sentence |
denotes |
Men, older adults (>65 years old), and persons with comorbidities are at risk for severe COVID‐19 and death. |
T171 |
14014-14212 |
Sentence |
denotes |
Countries have successfully suppressed transmission and mitigated needs for intensive care with robust case/contact detection (testing), isolation of infected/exposed persons, and social distancing. |
T172 |
14213-14386 |
Sentence |
denotes |
To stop the COVID‐19 pandemic, the challenge is for all countries to scale up and sustain prevention measures while awaiting the arrival of effective vaccines and therapies. |